Amphastar Pharmaceuticals
AMPH
146 hedge funds and large institutions have $549M invested in Amphastar Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 28 funds opening new positions, 53 increasing their positions, 44 reducing their positions, and 17 closing their positions.
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
20% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 44
15% more capital invested
Capital invested by funds: $476M → $549M (+$72.8M)
8% more funds holding
Funds holding: 135 → 146 (+11)
2.34% more ownership
Funds ownership: 54.89% → 57.23% (+2.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$10.5M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$4.59M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$3.5M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$3.49M |
| 5 |
JP Morgan Chase
New York
|
+$2.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$2.74M |
| 2 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
-$2.34M |
| 3 |
BlackRock
New York
|
-$2.03M |
| 4 |
Millennium Management
New York
|
-$1.94M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.88M |
AMPH Hedge Fund Activity: Q2 2021 in Review
146 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Amphastar Pharmaceuticals (AMPH) for Q2 2021, worth a combined $549M — up 15% from $476M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AMPH positions and 17 closed out — a net gain of 11 holders — while 53 added to existing stakes and 44 trimmed.
The largest buyer was Janus Henderson Group, opening a new position worth an estimated $10.5M. The largest seller was Invesco, cutting an estimated $2.74M.
- 146 institutional investors held Amphastar Pharmaceuticals (AMPH) as of Q2 2021, up from 135 in Q1 2021.
- Funds reported $549M of Amphastar Pharmaceuticals stock for Q2 2021, up 15% quarter-over-quarter.
- 28 funds opened new Amphastar Pharmaceuticals positions in Q2 2021 and 17 closed out, a net change of +11 holders.
- The largest Amphastar Pharmaceuticals buyer in Q2 2021 was Janus Henderson Group, an estimated $10.5M added.
- The largest Amphastar Pharmaceuticals seller in Q2 2021 was Invesco, an estimated $2.74M sold.
Based on aggregated 13F filings for Q2 2021.